Retatrutide 8 mg vial GLP3 (Triple G)

Retatrutide (LY3437943) peptide characteristics

Retatrutide peptide (LY3437943), also referred to as the GLP3, is a synthetic peptide analogue undergoing preclinical and clinical studies. The compound is designed as a triple agonist of GLP-1, GIP, and glucagon receptors (GCGR), which distinguishes it from classical mono (semaglutide) and dual (Tirzepatide) incretin agonists.

Retatrutide is a peptide composed of about 39 amino acids, containing sequence modifications that increase metabolic stability and resistance to enzymatic degradation. Due to its simultaneous modulation of three hormonal pathways, it is an important research reagent in projects involving regulation of appetite, metabolism and energy balance.

Mechanism of action of GLP3 - a scientific approach

In scientific publications, retatrutide peptide is described as a molecule that enables simultaneous modulation of three hormonal axes:

• GLP-1R - linked to satiety signaling and delayed gastric emptying,
• GIPR - important in studies of glucose metabolism and insulin response,
• GCGR - analyzed in the context of energy expenditure and metabolic regulation.

What has been observed in clinical trials of retatrutide (NEJM 2023, phase 2)

The following figures are from a phase 2 clinical trial published in the New England Journal of Medicine (PMID: 37366315) and were subsequently cited and discussed in a review of the scientific literature published in the PMC database (2025).

Weight change (least-squares mean) - observations in the research protocol

• 24 weeks (primary/key assessment point in phase 2):

• ca. -7.2% in group 1 mg
• up to approx. -17.5% in the 12 mg group
• vs. approx. -1.6% in placebo

• 48 weeks (secondary endpoint):

• ca. -8.7% in group 1 mg
• ca. -24.2% in the 12 mg group
• vs. approx. -2.1% in placebo

Response thresholds (48 weeks) - percentages of participants meeting reduction criteria

The same publication reported the percentages of subjects achieving certain thresholds of weight reduction (48 weeks). For the 12 mg dose in the study conditions were reported:

• ≥5%: 100%
• ≥10%: 93%
• ≥15%: 83%
  For placebo, respectively: 27% / 9% / 2%.

Safety profile of Retatrutide peptide - what studies have noted

In the available descriptions of retatrutide studies, the most commonly reported adverse events were as follows gastrointestinal and showed a dose dependency; the publications also point to the importance of careful dose escalation in research protocols.

Why Retatrutide peptide GLP3 is attracting so much interest

Retatrutide, also known as GLP3, is distinguished from other peptides by the fact that in laboratory studies it simultaneously acts on several key receptors involved in metabolism and energy balance. As a result, it is often chosen for research projects that rely on a broader view of the body's processes, rather than just analyzing a single mechanism.

Interest in this molecule also stems from data published in the scientific literature, where its research potential has been described in long-term observations under controlled conditions. This makes the retatrutide peptide seen as a modern research material that fits well with current developments in metabolism research.

Application under laboratory conditions

Retatrutide peptide (GLP3) reagent can be used as a research tool in projects involving:

• receptor signaling GLP-1/GIP/GCGR,
• appetite and energy balance regulation models,
• comparative studies with single- and dual-receptor agonists (in mechanistic terms).

Retatrutide peptide - purchase and availability online

If you are interested in retatrutide buy online, we offer this product as research material (Research Use Only) intended exclusively for laboratory applications and controlled research projects. Our online store allows you to purchase GLP3 retatrutide quickly and transparently without unnecessary paperwork, with a clear definition of the purpose of use and quality parameters.

Available options include:

• retatrutide for research,
• retatrutide in various amounts tailored to laboratory needs,
• order with a full description of the parameters and storage conditions.

The order process is designed to make it as easy as possible for you to buy online - whether you want to retatrutide GLP3 buy for research, or compare different forms of peptides in your laboratory. Before finalizing your order, we recommend reviewing the product's claimed purity and safe storage guidelines.

See also SLU-PP-332 500mcg capsule reagent 

Scientific sources:

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, N Engl J Med, 2023 (PMID: 37366315).

Retatrutide-A Game Changer in Obesity Pharmacotherapy, 2025, PMC12190491 (overview + summary of key results of phase 2).

This product is intended for research use only (Research Use Only). The information in the description is a review of the scientific literature (including NEJM 2023; PMID: 37366315) and does not constitute a medical or therapeutic recommendation.